Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

112.35 -0.53 (-0.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 785,510
Open 113.31
Bid (Size) 110.80 (100)
Ask (Size) 155.00 (100)
Prev. Close 112.88
Today's Range 110.93 - 115.04
52wk Range 45.91 - 122.20
Shares Outstanding 66,684,077
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗
The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management. 
Via Stocktwits
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill

Performance

YTD
+87.0%
+87.0%
1 Month
+5.4%
+5.4%
3 Month
+13.8%
+13.8%
6 Month
+76.5%
+76.5%
1 Year
+100.5%
+100.5%

More News

Read More
News headline image
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Rhythm Pharmaceuticals's Earnings: A Preview ↗
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reports Mixed Q3 2025 Results ↗
Via Chartmill
News headline image
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Under-the-Radar Stocks That Could Soar ↗
Via The Motley Fool
News headline image
Peering Into Rhythm Pharmaceuticals's Recent Short Interest ↗
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Analysts Have This To Say About Rhythm Pharmaceuticals ↗
Via Benzinga
News headline image
Rhythm (RYTM) Q2 Revenue Jumps 67% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Reports Mixed Q2 2025 Earnings: Revenue Beat Overshadowed by Wider Losses ↗
Via Chartmill
News headline image
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?
Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market
What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?
The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 112.35
When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 12/23/25 04:00 PM ET
What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 7.49B
How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?
Rhythm Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.